A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 513,300 shares of SAGE stock, worth $2.79 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
513,300
Previous 553,396 7.25%
Holding current value
$2.79 Million
Previous $6.01 Million 38.43%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.02 - $13.08 $281,473 - $524,455
-40,096 Reduced 7.25%
513,300 $3.7 Million
Q2 2024

Aug 09, 2024

BUY
$10.58 - $17.9 $5.48 Million - $9.28 Million
518,296 Added 1476.63%
553,396 $6.01 Million
Q1 2024

May 13, 2024

BUY
$18.62 - $26.95 $653,562 - $945,945
35,100 New
35,100 $658,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $1.43 Million - $4.19 Million
85,600 New
85,600 $1.76 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $990,996 - $1.33 Million
-30,700 Reduced 70.74%
12,700 $497,000
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $1.19 Million - $1.65 Million
43,400 New
43,400 $1.4 Million
Q3 2020

Nov 13, 2020

SELL
$41.13 - $62.45 $11.8 Million - $17.8 Million
-285,800 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$25.95 - $43.15 $12 Million - $19.9 Million
-461,332 Reduced 61.75%
285,800 $11.9 Million
Q1 2020

May 14, 2020

BUY
$26.15 - $77.24 $16.6 Million - $49.2 Million
636,541 Added 575.58%
747,132 $21.5 Million
Q4 2019

Feb 13, 2020

BUY
$60.18 - $154.77 $6.66 Million - $17.1 Million
110,591 New
110,591 $7.98 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.